drugset / Trial / NCT00119158

Combination Therapy for Atopic Dermatitis

NCT00119158

RandomizedParallel-groupDouble-blindTreatment

Summary

Atopic dermatitis is a chronic relapsing disease with acute flares. The standard therapy is to treat acute flares using topical medications. The two most common classes of topical medications for atopic dermatitis (AD) are topical corticosteroids and topical calcineurin inhibitors. Pimecrolimus and topical corticosteroids exert their activity by different mechanisms, there may be a synergistic effect of the combination therapy. Therefore, a combination therapy may provide a faster resolution of severe skin lesions and consequently reduce the duration of the topical corticosteroid treatment. Another benefit of the combination therapy maybe the use of a lower potency corticosteroid to achieve the same degree of clearance. The hypothesis of this trial is that the combination of the two agents will lead to faster clearance than the single agent of topical corticosteroids.

Timeline

Start
2004-10
Primary completion
2005-06
Completion
2005-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Pimecrolimus Small molecule 1 %
Comparator Fluticasone Other / unclassified 0.05 %

Indications